ArticleFrontiers in neurology2017
Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease.
Article in Frontiers in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Quantifying articulatory impairments in neurodegenerative motor diseases: A scoping review and meta-analysis of interpretable acoustic features.International journal of speech-language pathology · 2023Pooled it
- The Sequence Effect Worsens Over Time in Parkinson's Disease and Responds to Open and Closed-Loop Subthalamic Nucleus Deep Brain Stimulation.Journal of Parkinson's disease · 2023Trial
- Striatal network dysfunction underlying speech impairment in early Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Effects of STN-DBS treatment on voice characteristics in patients with Parkinson's Disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Alpha-synuclein overexpression reduces neural activity within a basal ganglia vocal nucleus in a zebra finch model.PloS one · 2026Article
- The effect of subthalamic nucleus deep brain stimulation on speech metrics in Parkinson's disease.Parkinsonism & related disorders · 2025Article
- Speech Markers of Parkinson's Disease: Phonological Features and Acoustic Measures.Brain sciences · 2025Article
- Investigation of the voice handicaps in Parkinson's disease and determination of the clinical correlates.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Automatic speech analysis combined with machine learning reliably predicts the motor state in people with Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Methylphenidate differentially affects the social ultrasonic vocalizations of wild-type and prodromal Parkinsonian rats.Behavioral neuroscience · 2025Article
- Understanding the progression of Parkinson's disease: a review.BMJ neurology open · 2025Review
- Unveiling early signs of Parkinson's disease via a longitudinal analysis of celebrity speech recordings.NPJ Parkinson's disease · 2024Article
- Contributions of Speech Timing and Articulatory Precision to Listener Perceptions of Intelligibility and Naturalness in Parkinson's Disease.Journal of speech, language, and hearing research : JSLHR · 2024Article
- Vocal and tongue exercise in early to mid-stage Parkinson disease using the Pink1-/- rat.Brain research · 2024Article
- Kinect-based objective assessment of the acute levodopa challenge test in parkinsonism: a feasibility study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- A neurocomputational view of the effects of Parkinson's disease on speech production.Frontiers in human neuroscience · 2024Article
- Long-term effects of subthalamic nucleus deep brain stimulation on speech in Parkinson's disease.Scientific reports · 2023Article
- Artificial Intelligence-Based Voice Assessment of Patients with Parkinson's Disease Off and On Treatment: Machine vs. Deep-Learning Comparison.Sensors (Basel, Switzerland) · 2023Article
- Continuous theta burst stimulation over right cerebellum for speech impairment in Parkinson's disease: study protocol for a randomized, sham-controlled, clinical trial.Frontiers in aging neuroscience · 2023Article
- Premotor cortex is hypoactive during sustained vowel production in individuals with Parkinson's disease and hypophonia.Frontiers in human neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) patients are affected by hypokinetic dysarthria, characterized by hypophonia and dysprosody, which worsens with disease progression. Levodopa's (l-dopa) effect on quality of speech is inconclusive; no data are currently available for late-stage PD (LSPD).
objectiveTo assess the modifications of speech and voice in LSPD following an acute l-dopa challenge.
methodLSPD patients [Schwab and England score <50/Hoehn and Yahr stage >3 (MED ON)] performed several vocal tasks before and after an acute l-dopa challenge. The following was assessed: respiratory support for speech, voice quality, stability and variability, speech rate, and motor performance (MDS-UPDRS-III). All voice samples were recorded and analyzed by a speech and language therapist blinded to patients' therapeutic condition using
results24/27 (14 men) LSPD patients succeeded in performing voice tasks. Median age and disease duration of patients were 79 [IQR: 71.5-81.7] and 14.5 [IQR: 11-15.7] years, respectively. In MED OFF, respiratory breath support and pitch break time of LSPD patients were worse than the normative values of non-parkinsonian. A correlation was found between disease duration and voice quality (
conclusionSpeech is severely affected in LSPD. Although l-dopa had some effect on motor performance, including axial signs, speech and voice did not improve. The applicability and efficacy of non-pharmacological treatment for speech impairment should be considered for speech disorder management in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.